There are no approved treatments available for Stargardt disease, and other therapeutic approaches do not target its root cause. 따라서 SAR은 유럽과 미국에서 희귀의약품으로 지정되었습니다. Oxford BioMedica estimates the market opportunity for SAR totals approximately million.